Table 5. Post-therapeutic findings and clinical outcome.
|
Patient no. |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
| Pathological stage | pT3bpN1 | pT3bpN0 | pT2cpN0 | pT3bpN0 | pT3bpN0 | pT3bpN1 | pT3bpN0 | pT2cpN0 | pT3apN0 |
| Gleason score (resected specimen) | 4+5 | 4+5 | 4+3 | 4+5 | 5+4 | 4+5 | 4+5 | 4+5 | 3+4 |
| PSA before RP (day 56) | 30.13 | 9.12 | 14.94 | 22.49 | 12.34 | 4.16 | 14.52 | 8.34 | 11.32 |
| PSA changing rate (%)a | 120 | 97 | 95 | 67 | 104 | 78 | 90 | 85 | 84 |
| Evaluation of pathological effects | |||||||||
| Cytopathic effects | − | − | − | − | + | − | + | + | + |
| Lymphocytic infiltration | − | − | − | − | − | + | + | + | − |
| Overall effects | − | − | − | − | + | + | ++ | ++ | + |
| Evaluation of MRI findings | SD | SD | SD | SD | SD | SD | SD | SD | PR |
| PSA recurrence after RP (months) | − | 9.3 | − | 0 | 0 | 6 | 0 | 9.2 | 16.1 |
|
Patient no. |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | |
| Pathological stage | pT2cpN0 | pT3bpN0 | pT2cpN0 | pT2cpN0 | pT3bpN0 | pT3apN0 | pT2cpN0 | pT2cpN0 | pT2cpN0 |
| Gleason score (resected specimen) | 4+3 | 3+5 | 4+3 | 4+5 | 4+3 | 4+4 | 3+3 | 4+3 | 4+5 |
| PSA before RP (day 56) | 13 | 9.04 | 12.2 | 9.74 | 28.78 | 29.39 | 14.09 | 9.51 | 25.32 |
| PSA changing rate (%)a | 91% | 84% | 91% | 73% | 113% | 88% | 82% | 87% | 116% |
| Evaluation of pathological effects | |||||||||
| Cytopathic effects | + | + | − | + | + | + | + | + | + |
| Lymphocytic infiltration | + | − | + | + | + | + | + | + | + |
| Overall effects | ++ | + | + | ++ | ++ | ++ | ++ | ++ | ++ |
| Evaluation of MRI findings | SD | SD | SD | PR | SD | PR | SD | − | SD |
| PSA recurrence after RP (months) | 22.4 | − | 0 | − | − | − | − | − | 9.2 |
Abbreviations: MRI, magnetic resonance imaging; PR, partial response; PSA, prostate-specific antigen; RP, radical prostatectomy; SD, stable disease.
a
PSA changing rate (%): PAS on day 56/PSA on day 0 × 100.